Contineum Therapeutics (NASDAQ:CTNM) Announces Quarterly Earnings Results

Contineum Therapeutics (NASDAQ:CTNM) announced its quarterly earnings data on Wednesday. The company reported ($0.40) earnings per share for the quarter, beating the consensus estimate of ($0.41) by $0.01, Zacks reports.

Contineum Therapeutics Stock Performance

Shares of CTNM stock traded down $0.15 during trading on Friday, reaching $18.40. The company’s stock had a trading volume of 44,394 shares, compared to its average volume of 73,289. Contineum Therapeutics has a one year low of $13.27 and a one year high of $22.00. The business has a fifty day moving average price of $17.58 and a 200-day moving average price of $17.77.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the company. Robert W. Baird began coverage on Contineum Therapeutics in a research note on Tuesday, October 22nd. They set an “outperform” rating and a $32.00 price objective for the company. Royal Bank of Canada reduced their target price on Contineum Therapeutics from $32.00 to $31.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Baird R W raised Contineum Therapeutics to a “strong-buy” rating in a research note on Tuesday, October 22nd. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $29.25.

About Contineum Therapeutics

Contineum Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS).